RYTM rhythmtx.com Earnings growth forecast for next year
Rhythm Pharmaceuticals bases its peptide production on the capacities of contract manufacturing organizations, relying on global supply chains. The projection of the expected EPS growth rate demonstrates profit dynamics, where the value of 79.10 characterizes this level. Rhythm Pharmaceuticals outsources clinical trials and distribution to external partners, while strict regulations on the air transport of orphan drugs guarantee stable access to medications across global markets.
RYTM (rhythmtx.com): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Capital Rhythm Pharmaceuticals|RYTM - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Rhythm Pharmaceuticals, Inc.|RYTM - Company Total Debt Obligations|Debt to Book Capitalization Ratio Rhythm Pharmaceuticals|RYTM - Company Long-Term Liabilities|Company Short-Term Debt Rhythm Pharmaceuticals|Quick Ratio rhythmtx.com
- net income and valuation ratios data:
RYTM - Final Profit|Future Profit Rhythm Pharmaceuticals|RYTM - Market Cap to Earnings|Projected Price to Earnings Rhythm Pharmaceuticals|RYTM - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Rhythm Pharmaceuticals|RYTM - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Rhythm Pharmaceuticals|RYTM - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months rhythmtx.com|RYTM - Earnings per share increase in current year|Net earnings per share growth forecast for next year Rhythm Pharmaceuticals
- total revenue and sales volume data:
Initial company analysis:RYTM, Rhythm Pharmaceuticals Inc
Retaining a core of experts in genetic metabolism allows Rhythm Pharmaceuticals (RYTM) to scale its workforce for commercialization, which directly impacts consensus earnings forecasts. By analyzing this chart of expected EPS growth over 12 months, investors assess the trend of net income per share revisions, determining the business model's sensitivity to market changes and the risk of capital drawdown should analyst expectations decline.
Analysis of competing companies
ASND (Ascendis Pharma Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Corp|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year AKRO (akerotx.com)|Net earnings per share growth forecast for next year Metsera MTSR|MoonLake Immunotherapeutics AG (MLTX) - Expected net earnings per share growth next year|CRNX - Net earnings per share growth forecast for next year|NAMS: Net earnings per share growth forecast for next year|SLNO: Earnings growth forecast for next year|FOLD - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year 89bio|Agios (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Structure Pharma (GPCR)|Expected earnings per share growth for next year MiMedx Corp MDXG|Net earnings per share growth forecast for next year Rezolute, Inc. RZLT|Expected earnings per share trend next year LXRX|MBX Biosciences - Earnings growth forecast for next year|Expected earnings per share trend next year ALT (Altimmune Inc)|AARD (Aardvark Therapeutics Corp) - Expected earnings per share growth for next year|Expected net earnings per share growth next year Sagimet Biosciences Inc (SGMT)|Expected earnings per share growth for next year BIOA|BMEA (biomeafusion.com) - Projected earnings per share increase next year|Earnings growth forecast for next year QNCX|GUTS (Fractyl Health Inc.) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year vTv Therapeutics VTVT|ATPC - Expected earnings per share growth for next year|PLUR: Expected earnings per share growth for next year|Expected earnings per share trend next year SYBX (Synlogic, Inc.)|Lipocine (LPCN) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year MTNB (Matinas BioPharma Holdings)|SPRB (Spruce Biosciences, Inc.) - Earnings growth forecast for next year|GLTO: Expected earnings per share trend next year|Earnings growth forecast for next year CTCX|Earnings growth forecast for next year lumos-pharma.com (LUMO)|Net earnings per share growth forecast for next year Organovo ONVO|Expected earnings per share trend next year RDUS
